No Data
2024 ANNUAL REPORT
2024 Annual Report Summary
Lionco Pharmaceutical Group (603669.SH): Net loss of 0.131 billion yuan in 2024.
On April 18, Glorious Finance announced that Lionco Pharmaceutical Group (603669.SH) released its annual report for 2024, achieving revenue of 0.38 billion yuan during the reporting period, a year-on-year increase of 92.95%; net income attributable to shareholders of the listed company was -0.131 billion yuan; basic EPS was -0.18 yuan.
Lionco Pharmaceutical Group Passes Drug Consistency Evaluation for Anesthesia Adjunct Drug
Lionco Pharmaceutical Group (603669.SH): A subsidiary's injectable Vecuronium Bromide has passed the consistency evaluation for generic drugs.
On April 11, Gelonghui reported that Lionco Pharmaceutical Group (603669.SH) announced that its wholly-owned subsidiary Hainan Meilan Shike Pharmaceutical Co., Ltd. (referred to as "Meilan Shike") recently received the approval notice from the National Medical Products Administration for the "Vecuronium Bromide Injection" (referred to as "the Pharmaceutical"), which has passed the consistency evaluation of quality and efficacy for generic drugs. The Vecuronium Bromide Injection developed by the company is indicated primarily as an adjunct to general anesthesia, used for tracheal intubation during general anesthesia and muscle relaxation during surgery.
Some Shareholders Feeling Restless Over Lionco Pharmaceutical Group Co.,Ltd.'s (SHSE:603669) P/S Ratio
Some Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) Shareholders Look For Exit As Shares Take 31% Pounding
